Inhaled corticosteroids in COPD: friend or foe?
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …
[HTML][HTML] Pulmonary-intestinal cross-talk in mucosal inflammatory disease
Chronic obstructive pulmonary disease (COPD) and inflammatory bowel diseases (IBDs)
are chronic inflammatory diseases of mucosal tissues that affect the respiratory and …
are chronic inflammatory diseases of mucosal tissues that affect the respiratory and …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary …
GT Ferguson, KF Rabe, FJ Martinez… - The Lancet …, 2018 - thelancet.com
Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
[HTML][HTML] Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Background Patients with chronic obstructive pulmonary disease (COPD) with an
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …
[HTML][HTML] Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman… - … England Journal of …, 2016 - Mass Medical Soc
Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease …
S Pascoe, N Locantore, MT Dransfield… - The lancet Respiratory …, 2015 - thelancet.com
Background The short-term benefits of inhaled corticosteroids for patients with chronic
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …
cardiovascular disease. Treatments for airflow limitation might improve survival and both …
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort …
Background Early descriptions of patients admitted to hospital during the COVID-19
pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease …
pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease …
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …